High-rolling investors have positioned themselves bullish on Biogen (NASDAQ ... Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Perhaps before we get started, just like to note that this is Mike McDonnell's last quarterly presentation as CFO of Biogen ... So, you know, the race really that we are faced with is seeing ...

Biogen has become the latest company to join the race to develop gene editing as a therapy, in a potential $2 billion alliance with the University of Pennsylvania. At the moment, gene editing is ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...